GlassScriptPhysician profile
Michael Galen Gibbs
NPI 1063704641
$2,471.77
in general payments reported to CMS, 2019-2025
23 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $29.20 · 2021: $53.15 · 2022: $488 · 2023: $539 · 2024: $569 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $407.75 | 2022-2025 | |
| Abbvie INC. | $386.63 | 2022-2025 | |
| Neurelis, INC. | $234.00 | 2022-2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $226.61 | 2023-2025 | |
| Neuropace, INC. | $219.41 | 2022-2025 | |
| Biogen, INC. | $147.78 | 2023-2025 | Vumerity |
| Sunovion Pharmaceuticals INC. | $113.37 | 2019 | |
| Mdd US Operations, LLC | $109.39 | 2019 | |
| Sumitomo Pharma America, INC. | $91.91 | 2023-2024 | Aptiom |
| Ucb, INC. | $90.52 | 2022-2025 | Fintepla |
| Monteris Medical Corporation | $68.06 | 2022-2023 | Neuroblate |
| Emd Serono, INC. | $55.27 | 2023-2024 | Mavenclad |
| Catalyst Pharmaceuticals, INC. | $49.27 | 2024 | |
| Ceribell, INC. | $39.92 | 2023 | Ceribell Rapid Response Eeg |
| Zimmer Biomet Holdings, INC. | $36.23 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $31.81 | 2019-2021 | |
| Argenx US, INC. | $31.56 | 2023 | Vyvgart |
| Biohaven Pharmaceuticals, INC. | $29.20 | 2020 | |
| Medtronic USA, INC. | $28.93 | 2019 | |
| Lundbeck LLC | $26.54 | 2021 | |
| Acadia Pharmaceuticals INC | $19.45 | 2019 | |
| Pfizer INC. | $15.16 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.